Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quincy Bioscience receives investment

This article was originally published in The Tan Sheet

Executive Summary

A capital infusion from the investment group DaneVest Tech Fund I will help Quincy Bioscience market its "novel" dietary supplement Prevagen, the Madison, Wis.-based biotech announces Aug. 25. Quincy launched the brain cell protection supplement in 2007 and says the unquantified investment "will accelerate our goal to make Prevagen a national brand" (1"The Tan Sheet" Aug. 10, 2009). Prevagen's active ingredient apoaequorin comes from jellyfish and is a calcium-binding protein that helps buffer excess calcium from damaging aging neurons, Quincy says

You may also be interested in...

Brain Gain: Supplements And Nutraceuticals Expand Cognitive Health Science

The next generation of substances to slow cognitive decline and perhaps even prevent Alzheimer's disease may take a test run through the dietary supplement and nutraceutical markets

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.



Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts